CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models

References

• Bos JD, de Rie MA, Teunissen MB, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol. 2005; 152(6):1098–1107. doi: 10.1111/j.1365-2133.2005.06645.x.
   PubMed Web of Science ®Google Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110–2121. doi: 10.1056/NEJMra1100359.
   PubMed Web of Science ®Google Scholar
• Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018; 19(3):293–302. doi: 10.1007/s40257-017-0340-7.
   PubMed Web of Science ®Google Scholar
• Mao X, Yamagami J, Pan M. Editorial: mechanism and therapy of autoimmune skin diseases. Front Med (Lausanne). 2023;10:1143454. doi: 10.3389/fmed.2023.1143454.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72 Suppl 2(0 2):ii111–5. doi: 10.1136/annrheumdis-2012-202576.
   PubMedGoogle Scholar
• Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017; 451:1–14. doi: 10.1016/j.mce.2017.05.033.
   PubMed Web of Science ®Google Scholar
• Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol. 2011; 18(3):314–323. doi: 10.1016/j.chembiol.2011.01.012.
   PubMedGoogle Scholar
• O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012; 36(4):542–550. doi: 10.1016/j.immuni.2012.03.014.
   PubMed Web of Science ®Google Scholar
• Welsch K, Holstein J, Laurence A, et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017; 47(7):1096–1107. doi: 10.1002/eji.201646680.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016; 175(5):902–911. doi: 10.1111/bjd.14871.
   PubMed Web of Science ®Google Scholar
• Zhang J, Qi F, Dong J, et al. Application of baricitinib in dermatology. J Inflamm Res. 2022;15:1935–1941. doi: 10.2147/JIR.S356316.
   PubMed Web of Science ®Google Scholar
• Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis. J Eur Acad Dermatol Venereol. 2022; 36(11):1937–1946. doi: 10.1111/jdv.18263.
   PubMed Web of Science ®Google Scholar
• Shan S, Zhou Y, Yu J, et al. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis. Int Immunopharmacol. 2019; 77:105914. doi: 10.1016/j.intimp.2019.105914.
   PubMed Web of Science ®Google Scholar
• Fang Z, Hu Y, Dai J, et al. CS12192, a novel JAK3/JAK1/TBK1 inhibitor, synergistically enhances the anti-inflammation effect of methotrexate in a rat model of rheumatoid arthritis. Int J Mol Sci. 2022;23(21):13394.
   Web of Science ®Google Scholar
• Suzuki T, Nishiyama K, Kawata K, et al. Effect of the Lactococcus lactis 11/19-B1 strain on atopic dermatitis in a clinical test and mouse model. Nutrients. 2020; 12(3):763. doi: 10.3390/nu12030763.
   PubMed Web of Science ®Google Scholar
• Hedrick MN, Lonsdorf AS, Shirakawa AK, et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest. 2009; 119(8):2317–2329. doi: 10.1172/jci37378.
   PubMed Web of Science ®Google Scholar
• Wu R, Zeng J, Yuan J, et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J Clin Invest. 2018; 128(6):2551–2568. doi: 10.1172/JCI97426.
   PubMed Web of Science ®Google Scholar
• Singh TP, Zhang HH, Hwang ST, et al. IL-23- and imiquimod-induced models of experimental psoriasis in mice. Curr Protoc Immunol. 2019; 125(1):e71.
   PubMedGoogle Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015; 386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7.
   PubMed Web of Science ®Google Scholar
• Zhu X, Han R, Tian X, et al. The opposite effect of tapinarof between IMQ and IL-23 induced psoriasis mouse models. Exp Dermatol. 2023;33(1):e14862. doi: 10.1111/exd.14862.
   PubMed Web of Science ®Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi: 10.3389/fimmu.2019.02847.
   PubMed Web of Science ®Google Scholar
• Works MG, Yin F, Yin CC, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014; 193(7):3278–3287. doi: 10.4049/jimmunol.1400205.
   PubMed Web of Science ®Google Scholar
• Miwa T, Zhou L, Maldonado MA, et al. Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice. J Immunol. 2012; 189(11):5434–5441. doi: 10.4049/jimmunol.1201621.
   PubMed Web of Science ®Google Scholar
• Landolfi MM, Van Houten N, Russell JQ, et al. CD2-CD4-CD8- lymph node T lymphocytes in MRL lpr/lpr mice are derived from a CD2 + CD4 + CD8+ thymic precursor. J Immunol. 1993; 151(2):1086–1096. doi: 10.4049/jimmunol.151.2.1086.
   PubMed Web of Science ®Google Scholar
• Zhou L, Sun L, Wu H, et al. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Eur J Pharmacol. 2013; 715(1-3):230–237. doi: 10.1016/j.ejphar.2013.05.016.
   PubMed Web of Science ®Google Scholar
• Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT ­signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. doi: 10.1186/s12964-017-0177-y.
   PubMedGoogle Scholar
• Hasan M, Yan N. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res. 2016; 111:336–342. doi: 10.1016/j.phrs.2016.04.008.
   PubMed Web of Science ®Google Scholar
• Bieber T, Paller AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022; 36(9):1432–1449. doi: 10.1111/jdv.18225.
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Igyártó BZ, Gaspari AA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012; 12(2):114–124. doi: 10.1038/nri3150.
   PubMed Web of Science ®Google Scholar
• Man MQ, Hatano Y, Lee SH, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol. 2008; 128(1):79–86. doi: 10.1038/sj.jid.5701011.
   PubMed Web of Science ®Google Scholar
• Kokubo K, Onodera A, Kiuchi M, et al. Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis. Front Immunol. 2022;13:945063. doi: 10.3389/fimmu.2022.945063.
   PubMed Web of Science ®Google Scholar
• McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021; 398(10302):803–816. doi: 10.1016/S0140-6736(21)00438-4.
   PubMed Web of Science ®Google Scholar